What’s to become of the contract research organization (CRO) industry while the economy attempts to right itself? Frost Report on CROs
The information provided in a recent report by Frost and Sullivan shows that, the Clinical Research Organisation industry will persist to expand despite speculation resultant of the volatile economic climate we have recently gone through. In this climate, biotechnology and pharmaceutical organisations keep away from investing in internal capabilities for the conduct of their research and similarly rely on outsourcing to CROs.
The report has also warned that the “US CRO Markets-Key Therapeutic Areas” anticipate that struggling pharma and biotech companies will fail to meet the costs for trials currently underway. But this is not likely to be a lasting occurrence, suggests the report.
Senior industry analyst for Frost and Sullivan, Barath Shankar Subramanian revealed that the annual revenue growth for CROs has decreased from the 14-15% range to 10% this past year.
Expansion Forecasts – for pharmacology companies or CRO’s
However, he says that the good news is that it is anticipated that the annual revenues for the industry will increase twofold between now and the year 2015, increasing from $10.91 billion at present to $22.87 billion. He says this is likely to result of sponsor organisations assuming strategic alliances with services organisations or smaller CROs. “After 10 years of talking about such relationships, CROs and pharma companies are beginning to forge them,” Subramanian says.
Subramanian uses the huge Eli Lilly/Covance deal made in August last year to exemplify this claim, where Covance has contracted out $1.6 billion worth of drug development projects to Lilly for the next 10 years.
“That’s the flavour of the season,” Subramanian says. “We’re seeing some new models being explored when previously it was purely transactional, with CROs taking a wait and watch attitude toward strategic partnerships.”
In addition, partnerships with CROs or clinical pharmacology organisations enable small sponsors more time within the research cycle to investigate promising molecules. Beginner biotech and pharma firms used to out-licence their Phase I or Phase II; which resulted in a large amount of ambiguity for the future of the research study. In this day and age, conversely, more and more start-up firms are able to keep products in the pipeline for a longer period of time which in turn brings them closer to the market and this is due to the cost-effectiveness made possible by CROs. This is an optimistic outcome for the sponsor and the CRO.
Author Tip: clinical studies conducted in the UK by professional CRO’s are the best choice for aquiring the most accurate data.
* Make sure that you consult your doctor before taking any medical advice of any kind.
Related posts:
- Free Credit Report: A Must For Everyone Credit report is a very important statement to keep a...
- Film Industry Jobs I love to write about a variety of interesting topics....
- What the emergency budget means for the construction industry With Government spending cuts apparently affecting every area of our...
- What job industry most likely does not conduct background checks? Free Background checks conducted by Personnel Profiles have been helping...
- Passion of Market Research Conducting due diligence reports and market research is extremely important before you...